A role for paralog-specific sumoylation in histone deacetylase 1 stability

被引:35
作者
Citro, Simona [1 ]
Jaffray, Ellis [2 ]
Hay, Ronald T. [2 ]
Seiser, Christian [3 ]
Chiocca, Susanna [1 ]
机构
[1] European Inst Oncol, Dept Expt Oncol, I-20139 Milan, Italy
[2] Univ Dundee, Coll Life Sci, Wellcome Trust Ctr Gene Regulat & Express, Dundee DD1 5EH, Scotland
[3] Med Univ Vienna, Max F Perutz Labs, Dept Med Biochem, A-1030 Vienna, Austria
基金
奥地利科学基金会;
关键词
breast cancer; HDAC1; PIAS; SUMO; ubiquitin; IN-VIVO IDENTIFICATION; TRANSCRIPTIONAL ACTIVITY; PROTEASOME INHIBITORS; MASS-SPECTROMETRY; SUMO; EXPRESSION; CANCER; HDAC1; ACTIVATION; PROGNOSIS;
D O I
10.1093/jmcb/mjt032
中图分类号
Q2 [细胞生物学];
学科分类号
071013 [干细胞生物学];
摘要
Histone deacetylase 1 (HDAC1) is an essential epigenetic regulator belonging to a highly conserved family of deacetylases. Increased HDAC1 activity and expression often correlates with neoplastic transformation. Here we show how specific modification of HDAC1 by SUMO1, but not by SUMO2, facilitates HDAC1 degradation. Our findings reveal that SUMO1, but not SUMO2, conjugation to HDAC1 promotes HDAC1 ubiquitination and degradation. This is suggested by the observation that in non-tumorigenic mammary epithelial cells HDAC1 is preferentially conjugated to SUMO1 leading to HDAC1 proteolysis, whereas in breast cancer cells HDAC1 is more conjugated to SUMO2, promoting HDAC1 protein stability. SUMO E3 ligases play an important role in paralog-specific conjugation; in particular, the SUMO E3 ligase PIASy, which is overexpressed in breast cancer cells, selectively promotes the conjugation of HDAC1 to SUMO2. Therefore, cell environment affects paralog-specific sumoylation of HDAC1, whose conjugation to SUMO1 but not to SUMO2 facilitates its protein turnover. Our findings uncover a role for paralog-specific sumoylation of HDAC1 whose significance is emphasized by the use of HDAC inhibitors as anticancer drugs.
引用
收藏
页码:416 / 427
页数:12
相关论文
共 63 条
[1]
The development of proteasome inhibitors as anticancer drugs [J].
Adams, J .
CANCER CELL, 2004, 5 (05) :417-421
[2]
In Vivo Identification of Sumoylation Sites by a Signature Tag and Cysteine-targeted Affinity Purification [J].
Blomster, Henri A. ;
Imanishi, Susumu Y. ;
Siimes, Jenny ;
Kastu, Juha ;
Morrice, Nick A. ;
Eriksson, John E. ;
Sistonen, Lea .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2010, 285 (25) :19324-19329
[3]
A mechanism for inhibiting the SUMO pathway [J].
Boggio, R ;
Colombo, R ;
Hay, RT ;
Draetta, GF ;
Chiocca, S .
MOLECULAR CELL, 2004, 16 (04) :549-561
[4]
How accurate are cancer cell lines? [J].
Borrell, Brendan .
NATURE, 2010, 463 (7283) :858-858
[5]
Loss of protein inhibitors of activated STAT-3 expression in glioblastoma multiforme tumors: Implications for STAT-3 activation and gene expression [J].
Brantley, Emily C. ;
Nabors, L. Burton ;
Gillespie, G. Yancey ;
Choi, Youn-Hee ;
Palmer, Cheryl Ann ;
Harrison, Keith ;
Roarty, Kevin ;
Benveniste, Etty N. .
CLINICAL CANCER RESEARCH, 2008, 14 (15) :4694-4704
[6]
Histone deacetylase inhibitors specifically kill nonproliferating tumour cells [J].
Burgess, A ;
Ruefli, A ;
Beamish, H ;
Warrener, R ;
Saunders, N ;
Johnstone, R ;
Gabrielli, B .
ONCOGENE, 2004, 23 (40) :6693-6701
[7]
Hypoxia Inactivates the VHL Tumor Suppressor through PIASy-Mediated SUMO Modification [J].
Cai, Qiliang ;
Verma, Suhbash C. ;
Kumar, Pankaj ;
Ma, Michelle ;
Robertson, Erle S. .
PLOS ONE, 2010, 5 (03)
[8]
SUMO-Specific protease 1 is essential for stabilization of HIF1α during hypoxia [J].
Cheng, Jinke ;
Kang, Xunlei ;
Zhang, Sui ;
Yeh, Edward T. H. .
CELL, 2007, 131 (03) :584-595
[9]
SENP1 enhances androgen receptor-dependent transcription through desumoylation of histone deacetylase 1 [J].
Cheng, JK ;
Wang, DC ;
Wang, ZX ;
Yeh, ETH .
MOLECULAR AND CELLULAR BIOLOGY, 2004, 24 (13) :6021-6028
[10]
Citro Simona, 2013, Front Biosci (Schol Ed), V5, P544